title: Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial.
abstract: OBJECTIVE
  The purpose of the study was to assess the possible benefit of the combination vinorelbine (NVB)-cisplatin (DDP) in comparison with NVB alone in advanced non-small cell lung cancer (NSCLC), not treated previously. It also involved confirmation of the efficacy of vinorelbine as monotherapy.
  
  
  METHODS
  In this phase III trial, 231 eligible patients were stratified by centre and randomized to receive either NVB alone, 30 mg/m2/week or the combination of NVB 30 mg/m2/week and DDP 80 mg/m2/3 weeks. Patients were to be treated for a minimum of 6 weeks, with the first response assessment performed 9 weeks after the beginning of treatment.
  
  
  RESULTS
  The two groups differed in terms of objective response rates (16% and 43%, respectively, p = 0.0001) and median time to progression (10 weeks and 20 weeks, p = 0.0001). However, the difference was not significant for median survival time (32 weeks, 33 weeks, p = 0.48). The addition of DDP resulted in an increase in toxicity, in particular renal, hematologic, neurologic and emetic. This toxicity led to treatment discontinuation in 8% and 21% of patients, respectively. Respectively 3% and 13% of patients stopped treatment early during objective response (toxicity or refusal).
  
  
  CONCLUSIONS
  The NVB-DDP combination increased objective response rates and time to progression in comparison with NVB alone, but did not influence the survival of patients. The activity of NVB in the treatment of advanced NSCLC was confirmed.
authors.affiliation: Department of Biostatistics and Medical Informatics, St. Louis Hospital, Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Depierre
authors.forename: C
authors.initials: C
authors.lastname: Chastang
authors.forename: E
authors.initials: E
authors.lastname: Quoix
authors.forename: B
authors.initials: B
authors.lastname: Lebeau
authors.forename: F
authors.initials: F
authors.lastname: Blanchon
authors.forename: N
authors.initials: N
authors.lastname: Paillot
authors.forename: E
authors.initials: E
authors.lastname: Lemarie
authors.forename: B
authors.initials: B
authors.lastname: Milleron
authors.forename: D
authors.initials: D
authors.lastname: Moro
authors.forename: J
authors.initials: J
authors.lastname: Clavier
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D011446:Prospective Studies; D016019:Survival Analysis; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077235:Vinorelbine
chemical_list: D000970:Antineoplastic Agents; D014747:Vinblastine; D002945:Cisplatin; D000077235:Vinorelbine